Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 8/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128797 | 0.93 | TRPV1 (0.34) | ACSS2CXCR4TRPV1TP53NOD1 | |
| SCHEMBL7070345 | 0.90 | TRPV1 (0.37) | ACSS2TRPV1NOD1ALDH1A1HSD17B10 | |
| SCHEMBL7071888 | 0.90 | ACSS2 (0.41) | ACSS2TRPV1NOD1KDM4EALDH1A1 | |
| SCHEMBL7069727 | 0.86 | TRPV1 (0.36) | ACSS2TRPV1NOD1ALDH1A1HSD17B10 | |
| SCHEMBL7072408 | 0.84 | ACSS2 (0.37) | ACSS2CXCR4TRPV1TP53NOD1 | |
| SCHEMBL7071922 | 0.84 | NOD1 (0.37) | ACSS2CXCR4TRPV1TP53NOD1 | |
| SCHEMBL7071907 | 0.81 | NOD1 (0.38) | ACSS2TRPV1TP53NOD1MTNR1A | |
| SCHEMBL7067795 | 0.80 | F9 (0.37) | ACSS2 | |
| SCHEMBL7073124 | 0.79 | ACSS2 (0.38) | ACSS2TRPV1TP53ALDH1A1MTNR1A | |
| SCHEMBL7068332 | 0.79 | F2 (0.40) | TRPV1TP53NOD1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | ACSS2 609/4885CXCR4 2356/4885TRPV1 823/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | ACSS2 746/4885CXCR4 3142/4885TRPV1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.